Hologic Q4 Sales Fell On Lower COVID-19 Assay Sales; Guides FY22 Ahead Of Consensus

  • Hologic Inc HOLX posted fourth-quarter revenues of $1.32 billion, down 2.3% Y/Y but beating analysts' average estimate of $1.04 billion. The drop in sales was driven by lower molecular diagnostic and COVID-19 assay sales.
  • Q4 product revenues dropped 5% Y/Y to $1.14 billion, while service and other revenues rose 24% to $178.7 million.
  • Hologic reported Q4 diagnostics revenues of $836.8 million, down 11%. Excluding its divested blood screening business, diagnostics revenues were $820.5 million, down 12%.
  • Outside of its diagnostics business, Hologic's Q4 breast health product revenues rose 16% to $334.2 million, while its skeletal health product revenues were up 27% to $23.6 million. Gynecology surgical revenues increased 22% to $122.0 million.
  • Q4 adjusted EPS declined 22% to $1.61 but surpassed the consensus of $1.01.
  • Guidance: For Q1 FY22, Hologic expects revenue of $1.10 billion - $1.15 billion (consensus $991.63 million) and adjusted EPS of $1.15 - $1.25 (consensus $0.96).
  • For FY22, the firm expects revenues of $3.75 billion - $4.00 billion (consensus of $3.87 billion), with adjusted EPS of $3.55 - $3.85 (consensus $3.69).
  • Price Action: HOLX shares closed at $72.68 on Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!